InvestorsHub Logo
Followers 71
Posts 11465
Boards Moderated 0
Alias Born 12/25/2009

Re: None

Friday, 06/02/2017 7:23:31 AM

Friday, June 02, 2017 7:23:31 AM

Post# of 1162
Bristol-Myers and Seattle Genetics advance Opdivo/Adcetris combo for HL into Phase 3

Jun. 2, 2017 7:07 AM ET|About: Bristol-Myers Squibb C... (BMY)|By: Douglas W. House, SA News Editor

Motivated by encouraging results in a Phase 1/2 study, Bristol-Myers Squibb (NYSE:BMY) and Seattle Genetics (NASDAQ:SGEN) have entered into a collaboration agreement to assess the combination of Opdivo (nivolumab) and ADCETRIS (brentuximab vedotin) in a Phase 3 clinical trial in patients with relapsed/refractory or stem cell transplant-ineligible advanced classical Hodgkin lymphoma (HL).

The late-stage open-label study should commence in the next month or two.

Opdivo is a PD-1 immune checkpoint inhibitor. ADCETRIS is an antibody-drug conjugate (ADC) consisting of a CD30-targeting monoclonal antibody attached to a cytotoxic agent called monomethyl auristatin E.
__________________________________________
https://seekingalpha.com/news/3271235-bristol-myers-seattle-genetics-advance-opdivo-adcetris-combo-hl-phase-3?app=1&uprof=46#email_link

BMY
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent BMY News